Institute for Systems Biology Moscow to Present Research Results in HCV therapeutic area at ACoP7 Conference

events
Conference
October 22, 2016

Moscow, Russia - October 22nd, 2016. Institute for Systems Biology Moscow (www.insysbio.ru), a private research organization focused on application of quantitative system pharmacology (QSP) modeling to different stages of drug research and development, today announced their participation and poster presentation at ACoP7 to be held in Bellevue, WA on October 23-26, 2016.

Oleg Demin Jr, Senior Modeler at Institute for Systems Biology Moscow will present two posters on application of QSP modelling in HCV therapeutic area.

Poster entitled "Prediction of Treatment Efficacy of Direct Antiviral Agent Combinations in Chronic Hepatitis C Patients Using Quantitative Systems Pharmacology Modeling Approach" on Monday, October 24th, 2016 at 7:30am to 9:30am. The poster will demonstrate predictions of results of ongoing clinical trials of direct antiviral agents combinations for chronic hepatitis C patients with genotype 1. QSP model predicts primary endpoint SVR12 quantifying percent of patients with undetectable hepatitis C virus during 12 weeks after treatment completion. Poster ID is M45.

Poster entitled “Modeling of immune response suppression by hepatitis C virus and nivolumab treatement in chronic hepatitis C patients using quantitative systems pharmacology approach" on Tuesday, October 25th, 2016 at 7:30am to 9:00am. The poster will demonstrate how QSP model can describe suppression of immune response by hepatitis C virus. The model was applied to predict and explore results of treatment of chronic hepatits C patients with PD-1 inhibitor nivolumab. Poster ID is T56.

About Institute for Systems Biology Moscow (ISBM):

Institute for Systems Biology Moscow, Ltd. (www.insysbio.ru) is a leading R&D company providing services for mathematical modeling in drug research and development. ISBM is one of the pioneers in quantitative system pharmacology (QSP) modeling and simulation services and has been working on the market for more than 10 years. The company’s aim is to assist right decisions on the critical stages of drug research and development. ISBM team continuously improves methods and tools for biological modeling. Moreover, company works with students and postgraduates forming professional community of QSP-modelers. Company has published a lot of scientific studies, and has presented at major international conferences of the field. The ISBM innovative approach has become an integral part of the drug development process implemented by our strategic partners: nowadays there are more than 100 completed projects in collaboration with leaders of pharma industry.

Media contact:
Maria Maximova, media@insysbio.ru

March 2022
MoTuWeThFrSaSu
 
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
1. 17 Mar 2022 14:17 InSysBio to present posters at AACR Annual Meeting 2022 InSysBio team is going to present its posters in frames of American Association for Cancer Research (AACR) Annual Meeting 2022 which is to be held April 8-13, New Orleans, Louisiana. The abstracts have been published on AACR website and E-Posters are going to be presented if frames of Poster Sessions
18
19
20
21
22
23
24
25
26
27
28
29
1. 29 Mar 2022 13:44 InSysBio to take part in QSPC2022 InSysBio announces its participation in Quantitative Systems Pharmacology Conference 2022 (QSPC2022) which is to be held on April 20-22, 2022, Leiden, The Netherlands. InSysBio team is going to present its QSP tools at the Booth and 15 posters in frames of the Conference
30
31
   
Upcoming Events
Tags
Latest News
11.07
InSysBio team to publish the new article in Journal of Pharmacokinetics and Pharmacodynamics
24.05
InSysBio to establish a new legal entity in Cyprus
25.04
InSysBio's ASCPT 2022 Micro-Theater Session on YouTube
20.01
InSysBio to release Immune Response Template v. 3.6.0
23.12
InSysBio to update CYTOCON DB and CYTOCON DB Open